Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers

Trial Profile

A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB-103 (Primary)
  • Indications Brain metastases; Meningeal carcinomatosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 13 Aug 2019 According to a Mustang Bio media release, the City of Hope research team led by Saul Priceman, Ph.D (assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation), along with the clinical lead Jana Portnow, M.D., Associate Clinical Professor in the Department of Medical Oncology & Therapeutics Research, will use the funds to support this study.
    • 13 Aug 2019 According to a Mustang Bio media release, City of Hope has received a $9.28 million grant from the California Institute for Regenerative Medicine (CIRM) to fund this ongoing phase 1 study.
    • 26 Jun 2019 Planned number of patients changed from 30 to 39.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top